Use of sugarcane molasses for culture of Clostridium chauvoei.

B. Micalizzi,A. M. Stefanini de Guzmán

DOI: https://doi.org/10.1093/CLINIDS/20.SUPPLEMENT_2.S382

IF: 20.999

1995-06-01

Clinical Infectious Diseases

Abstract:

What problem does this paper attempt to address?

Thromboxane a2: biosynthesis and effects on platelets.

E. Granström,U. Diczfalusy,M. Hamberg,G. Hansson,C. Malmsten,B. Samuelsson

Abstract:
Alternatives to conventional antimicrobial drugs: a review of future prospects

David H Lloyd

DOI: https://doi.org/10.1111/j.1365-3164.2012.01042.x

Abstract:Background: Growing antimicrobial resistance poses the threat that before long no suitable drugs will be available for treatment of common infections. This review examines promising new strategies for treatment and control of microbial diseases, with an emphasis on staphylococcal infection. New drugs and targets: Advances in microbial genomics have provided tools identifying many new targets for antimicrobial drugs. Of particular interest amongst these are inhibition of microbial efflux pump activity, interruption or diversion of riboswitches controlling bacterial metabolism, and metagenomics, which allows analysis of genes from unculturable organisms. Biological approaches: Advances are also being made in biological systems for disease control, with the exploitation of antimicrobial peptides to attack micro-organisms and modulate immune responses, and the use of bacteriophages or their lysins to eliminate bacteria. There are new approaches in the development and targeting of vaccines and immunoglobulin preparations based on advanced knowledge of microbial physiology and immunoregulation. Working with the biome: With increasing recognition of the value of the normal microbiota in modulating immunity and the establishment of pathogens, there is growing interest in understanding the mammalian microbiome. Strategies are being developed to promote or maintain the normal microbiota, including the use of probiotics, and there is re-evaluation of the potential of bacterial interference. Looking ahead: Whilst these approaches are likely to generate new methods of disease control, few will yield usable products within the near future. There will be a continuing need for careful use of existing drugs based on firm diagnosis, rigorous hygiene and prudent antimicrobial stewardship.
Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights

Jordi Rello,Francesca Romana Parisella,Antonio Perez

DOI: https://doi.org/10.1080/17512433.2019.1619454

2019-05-27

Expert Review of Clinical Pharmacology

Abstract:Introduction: The rise of antibiotic resistance, the limited efficacy and the adverse events associated with antibiotics have urged the development of alternative measures to treat bacterial infections. Novel therapies which are pathogen specific and are safer to the healthy microbiome are being developed.Areas covered: This manuscript provides a compact overview of the feasibility and clinical impact of the latest novel therapies, with a focus on monoclonal antibodies (mAbs), vaccines, stem cells, bacteriophages, and liposomes. This is a follow-up of a previous manuscript (doi: 10.1080/17512433.2016.1241141); a database search (PubMed, EMBASE, Cochrane) was used to identify recently published literature (from January 2016) which was not covered in the previous publication.Expert opinion: Among non-traditional agents, monoclonal antibodies have not been as successful as in other therapeutic areas. In particular many are developed to prevent hospital-acquired infections caused by S. aureus or P. aeruginosa and, so far, results have been overall disappointing. Stem cells and bacteriophages still have a long way to go. Vaccines are always desirable to prevent infections but again there is a lack of confirmatory results. Broad spectrum liposomes have shown promising results in treating severely infected patients and could be game changers in patient management.

pharmacology & pharmacy
Defeating Antibiotic-Resistant Bacteria: Exploring Alternative Therapies for a Post-Antibiotic Era

Chih-Hung Wang,Yi-Hsien Hsieh,Zachary M. Powers,Cheng-Yen Kao

DOI: https://doi.org/10.3390/ijms21031061

IF: 5.6

2020-02-05

International Journal of Molecular Sciences

Abstract:Antibiotics are one of the greatest medical advances of the 20th century, however, they are quickly becoming useless due to antibiotic resistance that has been augmented by poor antibiotic stewardship and a void in novel antibiotic discovery. Few novel classes of antibiotics have been discovered since 1960, and the pipeline of antibiotics under development is limited. We therefore are heading for a post-antibiotic era in which common infections become untreatable and once again deadly. There is thus an emergent need for both novel classes of antibiotics and novel approaches to treatment, including the repurposing of existing drugs or preclinical compounds and expanded implementation of combination therapies. In this review, we highlight to utilize alternative drug targets/therapies such as combinational therapy, anti-regulator, anti-signal transduction, anti-virulence, anti-toxin, engineered bacteriophages, and microbiome, to defeat antibiotic-resistant bacteria.

biochemistry & molecular biology,chemistry, multidisciplinary
Novel targets to develop new antibacterial agents and novel alternatives to antibacterial agents

Tafere Mulaw Belete

DOI: https://doi.org/10.1016/j.humic.2019.01.001

2019-03-01

Human Microbiome Journal

Abstract:Antibacterial agents have saved many lives and helped the growth of modern medicine over the past half century. The emergence of drug resistance, jeopardizing the effectiveness of these life-saving treatments. This clearly highlights the urgent need for new and improved antibacterial drugs with a novel target and new molecular structure agent to obviate cross-resistance. This paper reviewed the possible new ways to discover novel antibacterial agents. The most widely studied new bacterial targets for novel drug development are quorum sensor biosynthesis, bacterial virulence factor, bacteria cell division machinery, Bacterial cell wall synthesis, PDF inhibitor, isoprenoid biosynthesis, shikimate synthesis pathway, biofilm synthesis and fatty acid biosynthesis. These new discovery routes have given rise to agents that are in preclinical trials. This review also discusses the alternatives approaches that act bacteria or any approaches that target the host. The most advanced approaches that are on clinical development are phages and other approaches that are on preclinical development are antimicrobial peptides. These alternatives ways may use as adjunctive therapies, which suggest that conventional antibacterial agents are still essential.
Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

Roderich Süssmuth,Marcel David Kulike-Koczula,Peng Gao,Simone Kosol

DOI: https://doi.org/10.1002/anie.202414325

2024-11-30

Angewandte Chemie International Edition

Abstract:In the fight against bacterial infections, particularly those caused by multi-resistant pathogens, the need for new antibacterials is undoubted in scientific communities. and is by now also widely perceived by the general population. However, the antibacterial research landscape has changed considerably over the past years. The majority of big pharma companies has left the field and thus, the decline in R&D on antibacterials severely impacts the drug pipeline. In past years, antibacterial research increasingly relies on smaller companies or academic research institutions, which mostly have only limited financial resources, to carry a drug discovery and development process from the beginning and through the clinical phases. This review formulates the requirements for an antibacterial in regard of targeted pathogens and resistance mechanisms. Strategies are shown for the discovery of new antibacterial structures originating from natural sources, chemical synthesis and more recent AI approaches. This is complemented by principles for the computer-aided design of antibacterials and the refinement of a lead structure. The second part of the article comprises a compilation of promising antibacterial molecules classified according to bacterial target areas. Aspects of the origin, the antibacterial spectrum, resistance and the current development status of the presented drug molecules are highlighted.

chemistry, multidisciplinary
Novel antibacterial agents for the treatment of serious Gram-positive infections

Darren Abbanat,Mark Macielag,Karen Bush

DOI: https://doi.org/10.1517/13543784.12.3.379

Abstract:With the continuing development of clinical drug resistance among bacteria and the advent of resistance to the recently released agents quinupristin-dalfopristin and linezolid, the need for new, effective agents to treat multi-drug-resistant Gram-positive infections remains important. This review focuses on agents presently in clinical development for the treatment of serious multidrug-resistant staphylococcal, enterococcal and pneumococcal infections, including methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and penicillin-resistant Streptococcus pneumoniae. Agents to be discussed that affect the prokaryotic cell wall include the antimethicillin-resistant S. aureus cephalosporins BAL9141 and RWJ-54428, the glycopeptides oritavancin and dalbavancin and the lipopeptide daptomycin. Topoisomerase inhibitors include the fluoroquinolones gemifloxacin, sitafloxacin and garenoxacin. Protein synthesis inhibitors are represented by the ketolides telithromycin and cethromycin, the oxazolidinones and the glycylcycline tigecycline. Although each of these compounds has demonstrated antibacterial activity against antibiotic-resistant pathogens, their final regulatory approval will depend on an acceptable clinical safety profile.
Beyond Antibiotics: What the Future Holds

Payam Benyamini

DOI: https://doi.org/10.3390/antibiotics13100919

2024-09-26

Antibiotics

Abstract:The prevalence of multidrug resistance (MDR) and stagnant drug-development pipelines have led to the rapid rise of hard-to-treat antibiotic-resistant bacterial infections. These infectious diseases are no longer just nosocomial but are also becoming community-acquired. The spread of MDR has reached a crisis level that needs immediate attention. The landmark O'Neill report projects that by 2050, mortality rates associated with MDR bacterial infections will surpass mortality rates associated with individuals afflicted with cancer. Since conventional antimicrobials are no longer very reliable, it is of great importance to investigate different strategies to combat these life-threatening infectious diseases. Here, we provide an overview of recent advances in viable alternative treatment strategies mainly targeting a pathogen's virulence capability rather than viability. Topics include small molecule and immune inhibition of virulence factors, quorum sensing (QS) quenching, inhibition of biofilm development, bacteriophage-mediated therapy, and manipulation of an individual's macroflora to combat MDR bacterial infections.

pharmacology & pharmacy,infectious diseases
Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal

Antonio Tarín-Pelló,Beatriz Suay-García,María-Teresa Pérez-Gracia

DOI: https://doi.org/10.1080/14787210.2022.2078308

2022-06-02

Abstract:Antibiotic resistance is one of the biggest public health threats worldwide. Currently, antibiotic-resistant bacteria kill 700,000 people every year. These data represent the near future in which we find ourselves, a 'post-antibiotic era' where the identification and development of new treatments are key. This review is focused on the current and emerging antimicrobial therapies which can solve this global threat. Through a literature search using databases such as Medline and Web of Science, and search engines such as Google Scholar, different antimicrobial therapies were analyzed, including pathogen-oriented therapy, phagotherapy, microbiota and antivirulent therapy. Additionally, the development pathways of new antibiotics were described, emphasizing on the potential advantages that the combination of a drug repurposing strategy with the application of mathematical prediction models could bring to solve the problem of AMRs. This review offers several starting points to solve a single problem: reducing the number of AMR. The data suggest that the strategies described could provide many benefits to improve antimicrobial treatments. However, the development of new antimicrobials remains necessary. Drug repurposing, with the application of mathematical prediction models, is considered to be of interest due to its rapid and effective potential to increase the current therapeutic arsenal. Antibiotic resistance is currently one of the biggest public health threats worldwide. Right now, antibiotic-resistant bacteria kill 700,000 people every year. Many of the available antibiotics are useless against drug resistant bacteria. The present and near future in which we find ourselves is a post-antibiotic era, where the antibiotics we have are unable to combat the bacterial infections that are emerging. In this review, published studies were accessed to explore different techniques that are available to improve existing treatment options. Currently, these strategies cannot replace antibiotic therapy. The reviewed knowledge presents these alternatives as adjuvants to antibiotic treatments. Therefore, research into new antibiotics remains important. This review exposes that the repurposing of known drugs as antibiotics could contribute to the cost-effective search of new antibiotics in a faster and cost-effective way compared to traditional development methods of new antibiotics. The review emphasizes the urgency of identifying new pharmacological targets that can aid in the development of new therapies, and to improve known alternative therapies. Drug repurposing can greatly shorten the time and cost of development of new antibiotics. This strategy adds to the value of certain commercialized molecules, recovering part of the investment made by the pharmaceutic industry. In addition, it provides greater knowledge about other alternative antibiotic therapies and about the mechanisms by which bacteria develop antibiotic resistance.

pharmacology & pharmacy,infectious diseases,microbiology
Bacteriophages show promise as antimicrobial agents

J. Alisky,K. Iczkowski,A. Rapoport,N. Troitsky

DOI: https://doi.org/10.1016/s0163-4453(98)92874-2

IF: 28.2

1998-01-01

Journal of Infection

Abstract:The emergence of antibiotic-resistant bacteria has prompted interest in alternatives to conventional drugs. One possible option is to use bacteriophages (phage) as antimicrobial agents. We have conducted a literature review of all Medline citations from 1966-1996 that dealt with the therapeutic use of phage. There were 27 papers from Poland, the Soviet Union, Britain and the U.S.A. The Polish and Soviets administered phage orally, topically or systemically to treat a wide variety of antibiotic-resistant pathogens in both adults and children. Infections included suppurative wound infections, gastroenteritis, sepsis, osteomyelitis, dermatitis, empyemas and pneumonia; pathogens included Staphylococcus, Streptococcus, Klebsiella, Escherichia, Proteus, Pseudomonas, Shigella and Salmonella spp. Overall, the Polish and Soviets reported success rates of 80-95% for phage therapy, with rare, reversible gastrointestinal or allergic side effects. However, efficacy of phage was determined almost exclusively by qualitative clinical assessment of patients, and details of dosages and clinical criteria were very sketchy. There were also six British reports describing controlled trials of phage in animal models (mice, guinea pigs and livestock), measuring survival rates and other objective criteria. All of the British studies raised phage against specific pathogens then used to create experimental infections. Demonstrable efficacy against Escherichia, Acinetobacter, Pseudomonas and Staphylococcus spp. was noted in these model systems. Two U.S. papers dealt with improving the bioavailability of phage. Phage is sequestered in the spleen and removed from circulation. This can be overcome by serial passage of phage through mice to isolate mutants that resist sequestration. In conclusion, bacteriophages may show promise for treating antibiotic resistant pathogens. To facilitate further progress, directions for future research are discussed and a directory of authors from the reviewed papers is provided.

infectious diseases
Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens

Cleo Anastassopoulou,Stefanos Ferous,Aikaterini Petsimeri,Georgia Gioula,Athanasios Tsakris

DOI: https://doi.org/10.3390/pathogens13100896

IF: 3.7

2024-10-15

Pathogens

Abstract:The continued rise in antimicrobial resistance poses a serious threat to public health worldwide. The use of phages that can have bactericidal activity without disrupting the normal flora represents a promising alternative treatment method. This practice has been successfully applied for decades, mainly in Eastern Europe, and has recently been used as an emergency therapy for compassionate care in the United States. Here, we provide a comprehensive review of the pre-clinical and clinical applications of phage therapy concerning three major Gram-negative pathogens: Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. The advantages and the challenges of expanding the usage of phages as an alternative or adjunctive treatment for antimicrobial-resistant bacterial infections are discussed. We emphasize the virologic complexities of using the highly adaptable phage populations as molecular tools, along with antibiotic chemical compounds, to effectively combat rapidly coevolving pathogenic bacteria in the host microenvironment. Pre-clinical studies, isolated clinical reports and a few randomized clinical trials have shown that bacteriophages can be effective in treating multidrug-resistant bacterial infections. The ability of some phages to revert the resistance against antibiotics, and possibly also against the human complement and other phages, appears to be a great advantage of phage therapy despite the inevitable emergence of phage-resistant strains. Bacteriophages (or specific phage-derived products) can enhance antimicrobial efficacy by reducing bacterial virulence via the alteration of basic bacterial structures, primarily of the cellular wall and membrane. Although several issues remain open regarding their effective clinical application, it appears that phage-based therapeutics in combination with antibiotics can provide an effective solution to the spread of antimicrobial resistance.

microbiology
Newer antibacterial drugs for a new century

Gina Devasahayam,William M Scheld,Paul S Hoffman

DOI: https://doi.org/10.1517/13543780903505092

2010-01-07

Expert Opinion on Investigational Drugs

Abstract:IMPORTANCE OF THE FIELD: Antibacterial drug discovery and development has slowed considerably in recent years, with novel classes discovered decades ago and regulatory approvals tougher to get. Traditional approaches and the newer genomic mining approaches have not yielded novel classes of antibacterial compounds. Instead, improved analogues of existing classes of antibacterial drugs have been developed by improving potency, minimizing resistance and alleviating toxicity.AREAS COVERED IN THIS REVIEW: This article is a comprehensive review of newer classes of antibacterial drugs introduced or approved after year 2000.WHAT THE READER WILL GAIN: It describes their mechanisms of action/resistance, improved analogues, spectrum of activity and clinical trials. It also discusses new compounds in development with novel mechanisms of action, as well as novel unexploited bacterial targets and strategies that may pave the way for combating drug resistance and emerging pathogens in the twenty-first century.TAKE HOME MESSAGE: The outlook of antibacterial drug discovery, though challenging, may not be insurmountable in the years ahead, with legislation on incentives and funding introduced for developing an antimicrobial discovery program and efforts to conserve antibacterial drug use.

pharmacology & pharmacy
Antimicrobials: An update on new strategies to diversify treatment for bacterial infections

Tegan Hibbert,Zeljka Krpetic,Joe Latimer,Hollie Leighton,Rebecca McHugh,Sian Pottenger,Charlotte Wragg,Chloë E. James

DOI: https://doi.org/10.1016/bs.ampbs.2023.12.002

2024-03-17

Advances in Microbial Physiology

Abstract:Ninety-five years after Fleming's discovery of penicillin, a bounty of antibiotic compounds have been discovered, modified, or synthesised. Diversification of target sites, improved stability and altered activity spectra have enabled continued antibiotic efficacy, but overwhelming reliance and misuse has fuelled the global spread of antimicrobial resistance (AMR). An estimated 1.27 million deaths were attributable to antibiotic resistant bacteria in 2019, representing a major threat to modern medicine. Although antibiotics remain at the heart of strategies for treatment and control of bacterial diseases, the threat of AMR has reached catastrophic proportions urgently calling for fresh innovation. The last decade has been peppered with ground-breaking developments in genome sequencing, high throughput screening technologies and machine learning. These advances have opened new doors for bioprospecting for novel antimicrobials. They have also enabled more thorough exploration of complex and polymicrobial infections and interactions with the healthy microbiome. Using models of infection that more closely resemble the infection state in vivo, we are now beginning to measure the impacts of antimicrobial therapy on host/microbiota/pathogen interactions. However new approaches are needed for developing and standardising appropriate methods to measure efficacy of novel antimicrobial combinations in these contexts. A battery of promising new antimicrobials is now in various stages of development including co-administered inhibitors, phages, nanoparticles, immunotherapy, anti-biofilm and anti-virulence agents. These novel therapeutics need multidisciplinary collaboration and new ways of thinking to bring them into large scale clinical use.

microbiology,biochemistry & molecular biology
Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy

Dayeon Kang,Damayanti Bagchi,Irene A. Chen

DOI: https://doi.org/10.1002/adtp.202300355

IF: 5.003

2023-12-22

Advanced Therapeutics

Abstract:Abstract Antimicrobial resistance remains a critical global health concern, necessitating the investigation of alternative therapeutic approaches. With the diminished efficacy of conventional small molecule drugs due to the emergence of highly resilient bacterial strains, there is growing interest in the potential for alternative therapeutic modalities. As naturally occurring viruses of bacteria, bacteriophage (or phage) are being re‐envisioned as a platform to engineer properties that can be tailored to target specific bacterial strains and employ diverse antibacterial mechanisms. However, limited understanding of key pharmacological properties of phage is a major challenge to translating its use from preclinical to clinical settings. Here, this work reviews modern advancements in phage‐based antimicrobial therapy and discusses the in vivo pharmacokinetics and biodistribution of phage, addressing critical challenges in their application that must be overcome for successful clinical implementation.
Bacteriophages as a potential substitute for antibiotics: A comprehensive review

Shruti O. Kushwaha,Santosh Kumar Sahu,Virendra Kumar Yadav,Mayuri C. Rathod,Dhaval Patel,Dipak Kumar Sahoo,Ashish Patel

DOI: https://doi.org/10.1002/cbf.4022

2024-04-26

Cell Biochemistry and Function

Abstract:Over the years, the administration of antibiotics for the purpose of addressing bacterial infections has become increasingly challenging due to the increased prevalence of antimicrobial resistance exhibited by various strains of bacteria. Multidrug‐resistant (MDR) bacterial species are rising due to the unavailability of novel antibiotics, leading to higher mortality rates. With these conditions, there is a need for alternatives in which phage therapy has made promising results. Phage‐derived endolysins, phage cocktails, and bioengineered phages are effective and have antimicrobial properties against MDR and extensively drug‐resistant strains. Despite these, it has been observed that phages can give antimicrobial activity to more than one bacterial species. Thus, phage cocktail against resistant strains provides broad spectrum treatment and magnitude of effectivity, which is many folds higher than antibiotics. Many commercially available endolysins such as Staphefekt SA.100, Exebacase (CF‐301), and N‐Rephasin®SAL200 are used in biofilm penetration and treating plant diseases. The role of CMP1 phage endolysin in transgenic tomato plants in preventing Clavibacter michiganensis infection and the effectiveness of phage in protecting Atlantic salmon from vibriosis have been reported. Furthermore, phage‐derived endolysin therapy, such as TSPphg phage exogenous treatment, can aid in disrupting cell walls, leading to bacterial cell lysis. As animals in aquaculture and slaughterhouses are highly susceptible to bacterial infections, effective phage therapy instead of antibiotics can help treat poultry animals, preserve them, and facilitate disease‐free trade. Using bioengineered phages and phage cocktails enhances the effectiveness by providing a broad spectrum of phages and target specificity. Research is currently being conducted on clinical trials to confirm the efficacy of engineered phages and phage cocktails in humans. Although obtaining commercial approval may be time‐consuming, it will be beneficial in the postantibiotic era. This review provides an overview of the significance of phage therapy as a potential alternative to antibiotics in combating resistant bacterial strains and its application to various fields and emphasizes the importance of safeguarding and ensuring treatment efficacy.

cell biology,biochemistry & molecular biology
Bacteriophages as Alternatives to Antibiotics in Clinical Care

Danitza Romero-Calle,Raquel Guimarães Benevides,Aristóteles Góes-Neto,Craig Billington

DOI: https://doi.org/10.3390/antibiotics8030138

2019-09-04

Antibiotics

Abstract:Antimicrobial resistance is increasing despite new treatments being employed. With a decrease in the discovery rate of novel antibiotics, this threatens to take humankind back to a “pre-antibiotic era” of clinical care. Bacteriophages (phages) are one of the most promising alternatives to antibiotics for clinical use. Although more than a century of mostly ad-hoc phage therapy has involved substantial clinical experimentation, a lack of both regulatory guidance standards and effective execution of clinical trials has meant that therapy for infectious bacterial diseases has yet to be widely adopted. However, several recent case studies and clinical trials show promise in addressing these concerns. With the antibiotic resistance crisis and urgent search for alternative clinical treatments for bacterial infections, phage therapy may soon fulfill its long-held promise. This review reports on the applications of phage therapy for various infectious diseases, phage pharmacology, immunological responses to phages, legal concerns, and the potential benefits and disadvantages of this novel treatment.
Non-antibiotic therapies for infectious diseases

Christine F Carson,Thomas V Riley

Abstract:The emergence of multiple antibiotic resistant organisms in the general community is a potentially serious threat to public health. The emergence of antibiotic resistance has not yet prompted a radical revision of antibiotic utilisation. Instead it has prompted the development of additional antibiotics. Unfortunately, this does not relieve the underlying selection pressure that drives the development of resistance. A paradigm shift in the treatment of infectious disease is necessary to prevent antibiotics becoming obsolete and, where appropriate, alternatives to antibiotics ought to be considered. There are already several non-antibiotic approaches to the treatment and prevention of infection including probiotics, phages and phytomedicines. There is some evidence that probiotics such as Lactobacillus spp. or Saccharomyces boulardii are useful in the prevention and treatment of diarrhoea, including Clostridium difficile-associated diarrhoea that can be difficult to treat and recurs frequently. Bacteriophages have received renewed attention for the control of both staphylococcal and gastrointestinal infections. Phytomedicines that have been utilised in the treatment of infections include artesunate for malaria, tea tree oil for skin infections, honey for wound infections, mastic gum for Helicobacter pylori gastric ulcers and cranberry juice for urinary tract infections. Many infections may prove amenable to safe and effective treatment with non-antibiotics.
Bacteriophage therapy- a refurbished age-old potential strategy to treat antibiotic and multidrug resistant bacterial infections in future

Rajal Dave,Debashis Banerjee

DOI: https://doi.org/10.1007/s42770-024-01434-7

Abstract:The worldwide prevalence of antimicrobial resistance coupled with the unavailability of newer antibiotics, has brought the sharp focus back among the scientific community, towards the discovery of novel alternative therapeutics to tackle the menace. Consequently, in the current post-antibiotic era, 'Bacteriophage Therapy' has emerged as one of the most promising option to address this problem. Bacteriophages, actually discovered long back, has shown greater potential to kill various bacterial pathogens, including the resistant clinical ones. Some of the other advantages for the use of bacteriophage therapy to treat infectious diseases include, wider availability of these microorganisms in nature, host-specific action, absence of any significant side-effects in humans and most often also exhibiting a broader anti-bacterial potential. In the recent times, the potential of phage therapy has been demonstrated in various treatments, clinical trials and infection models across the globe, where even antibiotics have completely failed. To address the global threat of AMR, WHO and UN have jointly illustrated "One Health" approach, recently extending the context to bacteriophage therapy. Many pharmaceutical companies have also recently started employing bacteriophages for developing different kinds of formulations for catering to medical and other industries. It has even shown great effect as combinatorial therapy along with antibiotics, to treat or manage various critical antibiotic resistant clinical infections. This continuously expanding potential of the bacteriophages holds great promise in the future, in the fight against the rising threat of AMR globally.
Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics

Jayaseelan Murugaiyan,P. Anand Kumar,G. Srinivasa Rao,Katia Iskandar,Stephen Hawser,John P. Hays,Yara Mohsen,Saranya Adukkadukkam,Wireko Andrew Awuah,Ruiz Alvarez Maria Jose,Nanono Sylvia,Esther Patience Nansubuga,Bruno Tilocca,Paola Roncada,Natalia Roson-Calero,Javier Moreno-Morales,Rohul Amin,Ballamoole Krishna Kumar,Abishek Kumar,Abdul-Rahman Toufik,Thaint Nadi Zaw,Oluwatosin O. Akinwotu,Maneesh Paul Satyaseela,Maarten B. M. van Dongen

DOI: https://doi.org/10.3390/antibiotics11020200

2022-02-04

Antibiotics

Abstract:Antibiotic resistance, and, in a broader perspective, antimicrobial resistance (AMR), continues to evolve and spread beyond all boundaries. As a result, infectious diseases have become more challenging or even impossible to treat, leading to an increase in morbidity and mortality. Despite the failure of conventional, traditional antimicrobial therapy, in the past two decades, no novel class of antibiotics has been introduced. Consequently, several novel alternative strategies to combat these (multi-) drug-resistant infectious microorganisms have been identified. The purpose of this review is to gather and consider the strategies that are being applied or proposed as potential alternatives to traditional antibiotics. These strategies include combination therapy, techniques that target the enzymes or proteins responsible for antimicrobial resistance, resistant bacteria, drug delivery systems, physicochemical methods, and unconventional techniques, including the CRISPR-Cas system. These alternative strategies may have the potential to change the treatment of multi-drug-resistant pathogens in human clinical settings.
Next-Generation Antibiotics, Bacteriophage Endolysins, and Nanomaterials for Combating Pathogens

I G Shemyakin,V V Firstova,N K Fursova,I V Abaev,S Yu Filippovich,S G Ignatov,I A Dyatlov

DOI: https://doi.org/10.1134/S0006297920110085

Abstract:This review presents various strategies to fight causative agents of infectious diseases. Species-specific programmable RNA-containing antibiotics open up new possibilities for creating next-generation of personalized drugs based on microbiome editing and can serve as a new tool for selective elimination of pathogenic bacterial species while keeping intact the rest of microbiota. Another promising approach in combating bacterial infections is genome editing using the CRISPR-Cas systems. Expanding knowledge on the molecular mechanisms of innate immunity has been actively used for developing new antimicrobials. However, obvious risks of using antibiotic adjuvants aimed at activation of the host immune system include development of the autoimmune response with subsequent organ damage. To avoid these risks, it is essential to elucidate action mechanisms of the specific ligands and signal molecules used as components of the hybrid antibiotics. Bacteriophage endolysins are also considered as effective antimicrobials against antibiotic-resistant bacteria, metabolically inactive persisters, and microbial biofilms. Despite significant advances in the design of implants with antibacterial properties, the problem of postoperative infections still remains. Different nanomodifications of the implant surface have been designed to reduce bacterial contamination. Here, we review bactericidal, fungicidal, and immunomodulating properties of compounds used for the implant surface nanomodifications, such as silver, boron nitride nanomaterials, nanofibers, and nanogalvanic materials.

Use of sugarcane molasses for culture of Clostridium chauvoei.

Thromboxane a2: biosynthesis and effects on platelets.

Alternatives to conventional antimicrobial drugs: a review of future prospects

Alternatives to antibiotics in an era of difficult-to-treat resistance: new insights

Defeating Antibiotic-Resistant Bacteria: Exploring Alternative Therapies for a Post-Antibiotic Era

Novel targets to develop new antibacterial agents and novel alternatives to antibacterial agents

Fighting Antimicrobial Resistance: Innovative Drugs in Antibacterial Research

Novel antibacterial agents for the treatment of serious Gram-positive infections

Beyond Antibiotics: What the Future Holds

Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal

Bacteriophages show promise as antimicrobial agents

Phage-Based Therapy in Combination with Antibiotics: A Promising Alternative against Multidrug-Resistant Gram-Negative Pathogens

Newer antibacterial drugs for a new century

Antimicrobials: An update on new strategies to diversify treatment for bacterial infections

Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy

Bacteriophages as a potential substitute for antibiotics: A comprehensive review

Bacteriophages as Alternatives to Antibiotics in Clinical Care

Non-antibiotic therapies for infectious diseases

Bacteriophage therapy- a refurbished age-old potential strategy to treat antibiotic and multidrug resistant bacterial infections in future

Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics

Next-Generation Antibiotics, Bacteriophage Endolysins, and Nanomaterials for Combating Pathogens